IX
IXC.AU INVEX Therapeutics Ltd
- Market cap
- AUD 7.52M
- P/E
- -
- P/B
- 1.92x
- ROE
- -34.6%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IXC.AU undervalued?
Graham numberThe Graham number of INVEX Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INVEX Therapeutics Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-34.6%), below 10%.
ROA 1/1
Return on assets (-33.3%) is above the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-185.6%) is below the industry median (-5.3%).
Revenue Growth 0/2
Revenue did not grow over the past 3 years or is not reported.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.0 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.9x) is below the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
INVEX Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Thera…
Full company profileINVEX Therapeutics Ltd financial statements
INVEX Therapeutics Ltd annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 130.00 | 166K | 159K | 182K | 459K | 1.21M | 229K | - |
| Gross Profit | 396.00 | - | - | 182K | 459K | 1.21M | 229K | - |
| Operating Income | -232K | -3.29M | -2.44M | -4.03M | -8.55M | -2.13M | -709K | -1.54M |
| EBITDA | 149K | -3.29M | 159K | -4.14M | 338K | -720K | -951K | -1.54M |
| Net Income | -232K | -3.36M | -2.28M | -3.95M | -7.75M | -1.64M | -477K | -1.35M |
| EPS | 0.00 | -0.06 | -0.03 | -0.05 | -0.10 | -0.02 | -0.01 | -0.02 |
| Balance Sheet | ||||||||
| Total Assets | 12.4M | 26.4M | 32.7M | 29.5M | 22.8M | 6.12M | 5.47M | 4.06M |
| Total Liabilities | 935K | 2.02M | 659K | 1.00M | 1.57M | 432K | 221K | 153K |
| Shareholders' Equity | 11.4M | 24.4M | 32.1M | 28.5M | 21.2M | 5.69M | 5.25M | 3.91M |
| Cash & Short-term Investments | 12.2M | 26.3M | 32.7M | 29.3M | 22.5M | 6.03M | 5.38M | 4.02M |
| Cash Flow | ||||||||
| Operating Cash Flow | -230K | -1.60M | -1.68M | -3.38M | -6.87M | -2.44M | -653K | -1.36M |
| Capital Expenditure | 8.19K | 0.00 | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -238K | -1.60M | -1.68M | -3.38M | -6.87M | -2.44M | -653K | -1.36M |
| Ratios | ||||||||
| ROE | -2.0% | -13.8% | -7.1% | -13.9% | -36.5% | -28.9% | -9.1% | -34.6% |
| ROA | -1.9% | -12.7% | -7.0% | -13.4% | -34.0% | -26.8% | -8.7% | -33.3% |
| Net Profit Margin | -178,461.5% | -2,027.9% | -1,438.4% | -2,169.0% | -1,688.1% | -135.5% | -208.2% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INVEX Therapeutics Ltd dividends
INVEX Therapeutics Ltd has not paid dividends in the last 8 fiscal years.
Who owns INVEX Therapeutics Ltd
- Insiders 63.93%
- Institutions 0.00%
- Public & others 36.07%
- Shares outstanding 75.2M
- Free float 46.6M
INVEX Therapeutics Ltd company profile
- Company name
- INVEX Therapeutics Ltd
- Ticker
- IXC.AU
- ISIN
- AU0000048621
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 101 St Georges Terrace, Perth, WA, Australia, 6000
- Phone
- 61 8 6558 0886
- Website
- invextherapeutics.com
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of efficacious treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
INVEX Therapeutics Ltd management
1- Mr. Timothy Ryan SlateCompany Secretary